Onco Wiki / Maladie

Carcinome parathyroïdien

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-PARATHYROID-CARCINOMA
TypeMaladie
Alias
Carcinome parathyroïdien associé au CDC73Carcinome parathyroïdien associé à HRPT2Carcinome parathyroïdien associé au MEN1 (rare)Cancer de la parathyroïdeКарцинома прищитоподібної залози
Étatreviewed 2026-05-18 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-NCCN-NET-2025 SRC-NCCN-THYROID-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8140/3
icd_o_3_topography["C75.0"]
icd_10C75.0
who_classificationWHO Endocrine and Neuroendocrine Tumours 5th ed (2022): Parathyroid carcinoma — diagnostic criteria require evidence of invasion (capsular / vascular / soft-tissue / lymph node / metastasis) and not just atypical histology

Capacités

Notes

Diagnosis is histologic-plus-invasive (capsular / vascular / soft- tissue invasion or metastasis) — atypical adenoma alone is not parathyroid carcinoma. Germline CDC73 / HRPT2 testing recommended at diagnosis for any parathyroid carcinoma (HPT-JT cascade). Treatment: en-bloc resection of parathyroid + ipsilateral thyroid lobe + central lymph nodes (R0 is the strongest prognostic factor; do NOT shell out the tumor at index surgery). Recurrent / metastatic disease: re- resection where feasible; calcimimetic (cinacalcet) for hypercalcemia control; bisphosphonates / denosumab for skeletal disease; pembrolizumab in MSI-H / TMB-high subset. No standard cytotoxic regimen with consistent activity.

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Médicament

Indication

Signal d’alerte

Protocole thérapeutique